Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
| العنوان: | Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging |
|---|---|
| المؤلفون: | Walter P Maksymowych, Rebecca Bolce, Gaia Gallo, Emily Seem, Vladimir J Geneus, David M Sandoval, Mikkel Østergaard, Kurisu Tada, Xenofon Baraliakos, Atul Deodhar, Lianne S Gensler |
| المصدر: | Maksymowych, W P, Bolce, R, Gallo, G, Seem, E, Geneus, V J, Sandoval, D M, Østergaard, M, Tada, K, Baraliakos, X, Deodhar, A & Gensler, L S 2022, ' Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging ', Rheumatology, vol. 61, no. 11, pp. 4324-4334 . https://doi.org/10.1093/rheumatology/keac104 |
| بيانات النشر: | Oxford University Press (OUP), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adult, Inflammation, randomized clinical trials, Magnetic Resonance Imaging, C-Reactive Protein, Treatment Outcome, Double-Blind Method, ixekizumab, Rheumatology, inflammation, Antirheumatic Agents, Spondylarthritis, Humans, Pharmacology (medical), CRP, Axial Spondyloarthritis, AS, MRI |
| الوصف: | Objective To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials. Methods Biologic-naïve (COAST-V) or TNF inhibitor-experienced (COAST-W) adults with active r-axSpA received 80 mg ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W) or PBO or active reference [40 mg adalimumab every 2 weeks (ADAQ2W) in COAST-V. At week 16, patients receiving ixekizumab continued as assigned and patients receiving PBO or ADA were rerandomized 1:1 to IXEQ2W or IXEQ4W through week 52. Assessment of SpondyloArthritis international Society 40% (ASAS40) response rates were examined by baseline CRP (≤5 or >5 mg/l) and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI spine inflammation score ( Results In the COAST-V/W integrated dataset (N = 567), significantly more patients treated with ixekizumab achieved ASAS40 response at week 16 by CRP ≤5 mg/l (27% IXEQ4W, P 5 mg/l (39% IXEQ4W, P Conclusion Ixekizumab demonstrated efficacy in the treatment of AS/r-axSpA in patients with and without elevated CRP or evidence of spinal inflammation on MRI. Trial registration ClinicalTrials.gov (https://clinicaltrials.gov): NCT02696785, NCT02696798 |
| وصف الملف: | application/pdf |
| تدمد: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/keac104 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bf12151bebed0736f2e45173ec98b5d https://doi.org/10.1093/rheumatology/keac104 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7bf12151bebed0736f2e45173ec98b5d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14620332 14620324 |
|---|---|
| DOI: | 10.1093/rheumatology/keac104 |